Skip to main content
Quest Diagnostics

Quest Event at AAIC 2025: 

Advancing Alzheimer's Diagnostics with the Power of Combined Plasma Biomarkers

Live presentation at Alzheimer's Association International Conference (AAIC) 2025

Date: July 27-31, 2025

Location: Toronto, Canada

 

Quest Diagnostics Product Theater - Presentation

 

   -  Title: Advancing Alzheimer's Diagnostics with the Power of Combined Plasma Biomarkers

 

   -  Speakers:

        -  Dr Michael K. Racke, MD, Medical Director

           Neurology

        -  Darren Weber, Associate Scientific Director, R&D

           Protein Mass Spectrometry

 

   -  Presentation Overview: Multiple plasma biomarker

      values streamlined into a single analytical result

      offers a promising, scalable approach for evaluating

      individuals with cognitive impairment.

     

      This session will explore how combined biomarker

      analysis can support establishing the likelihood of

      amyloid pathology related to Alzheimer's disease,

      aiding in diagnostic decision making and care

      planning.

 

   -  When: Monday July 28 at 12:25 PM

 

   -  Location: Product Theater Stage B (#2)

 

Date:
Jul 29, 2025
Time:
12:25 AM - 01:25 AM ET
Presenter(s):

Dr Michael K. Racke, MD, Medical Director Neurology

Darren Weber, Associate Scientific Director, R&D Protein Mass Spectrometry

Specialties:
Neurology

Quest Diagnostics Neurology at AAIC

Quest Diagnostics will be exhibiting at the Alzheimer's Association International Conference (AAIC), the largest international conference on dementia research where breakthroughs and best practices will be shared and discussed.

Visit us at Booth #1190

Our Quest Diagnostics Neurology team is looking forward to discussing our latest innovations and clinical offerings--providing a deeper understanding of our commitment to advancing diagnostics along the cognitive care pathway.

Related content

Publication
Clinical Utility of Plasma Aβ42/40 Ratio by LC-MS/MS in Alzheimer’s Disease Assessment
Audio Podcast
Alzheimer’s Disease: A New Generation of Screenings and Therapies on the Horizon
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.